HRP20192101T1 - Inhibitori ezh2 - Google Patents
Inhibitori ezh2 Download PDFInfo
- Publication number
- HRP20192101T1 HRP20192101T1 HRP20192101TT HRP20192101T HRP20192101T1 HR P20192101 T1 HRP20192101 T1 HR P20192101T1 HR P20192101T T HRP20192101T T HR P20192101TT HR P20192101 T HRP20192101 T HR P20192101T HR P20192101 T1 HRP20192101 T1 HR P20192101T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- salt
- cancer
- methyl
- intended
- Prior art date
Links
- 101150090105 Ezh2 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 24
- -1 methoxy, 2-propoxy, methoxymethyl Chemical group 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 5
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- AGTKUHSJKOLBGH-JSRJAPPDSA-N 5-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2-[(1R)-1-[4-(3-methoxyazetidin-1-yl)cyclohexyl]ethyl]-3-methyl-7,8-dihydro-6H-thieno[3,2-c]azepin-4-one Chemical compound CC1=C(C(NC(=C1)C)=O)CN1C(C2=C(CCC1)SC(=C2C)[C@H](C)C1CCC(CC1)N1CC(C1)OC)=O AGTKUHSJKOLBGH-JSRJAPPDSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- AGTKUHSJKOLBGH-CEMLEFRQSA-N CC1=C(C(NC(=C1)C)=O)CN1C(C2=C(CCC1)SC(=C2C)[C@H](C)[C@@H]1CC[C@H](CC1)N1CC(C1)OC)=O Chemical compound CC1=C(C(NC(=C1)C)=O)CN1C(C2=C(CCC1)SC(=C2C)[C@H](C)[C@@H]1CC[C@H](CC1)N1CC(C1)OC)=O AGTKUHSJKOLBGH-CEMLEFRQSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 101000835860 Homo sapiens SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 1
- 102100025746 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Human genes 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229910052801 chlorine Chemical group 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Claims (24)
1. Spoj formule:
,
naznačen time što:
X je -CH2-ili-CH2-CH2-;
Y’ je -NR4R5, -CH(CH3)-cikloheksil-4-il-N-metil-N-metoksietil ili -CH(CH3)-cikloheks-4-il-azetidin-1-il, gdje azetidin-1-il može biti supstituiran s metoksi, 2-propoksi, metoksimetilom, metoksietoksi, ciklopropiloksi, ciklopropilmetoksi, pirazolilom, metilpirazolilom, triazolilom, pirolidinilom, tetrahidrofuraniloksi ili morfolinilom;
R4 je cikloheks-4-il, supstituiran s N-metil-N-metoksietilamino, N-metil-N-ciklopropilamino ili azetidin-1-ilom, gdje je azetidin-1-il supstituiran s metoksi, etoksi, metoksietoksi, ciklopropiloksi ili pirazolilom;
R5 je metil ili etil; i
R6 je metil ili klor;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj, ili njegova sol, u skladu s patentnim zahtjevom 1, naznačen time što je X -CH2-.
3. Spoj, ili njegova sol, u skladu s patentnim zahtjevom 1, naznačen time što je X -CH2-CH2-.
4. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što je Y’ -CH(CH3)-cikloheksil-4-il-N-metil-N-metoksietil ili -CH(CH3)-cikloheks-4-il-azetidin-1-il, gdje azetidin-1-il može biti supstituiran s metoksi, 2-propoksi, metoksimetilom, metoksietoksi, ciklopropiloksi, ciklopropilmetoksi, pirazolilom, metilpirazolilom, triazolilom, pirolidinilom, tetrahidrofuraniloksi ili morfolinilom.
5. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1-,4 naznačen time što je Y’ -CH(CH3)-cikloheks-4-il-azetidin-1-il, gdje azetidin-1-il može biti supstituiran s metoksi, 2-propoksi, metoksimetilom, metoksietoksi, ciklopropiloksi, ciklopropilmetoksi, pirazolilom, metilpirazolilom, triazolilom, pirolidinilom, tetrahidrofuraniloksi ili morfolinilom.
6. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je R6 metil.
7. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što je Y’ -NR4R5.
8. Spoj u skladu s bilo patentnim zahtjevom 1 ili 3, naznačen time što je
,
ili njegova farmaceutski prihvatljiva sol.
9. Spoj u skladu s patentnim zahtjevom 8, naznačen time što je 5-[(4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil]-2-{(1R)-1-[4-(3-metoksiazetidin-1-il)cikloheksil]etil}-3-metil-5,6,7,8-tetrahidro-4H-tieno[3,2-c]azepin-4-on, ili njegova farmaceutski prihvatljiva sol.
10. Spoj u skladu s patentnim zahtjevom 9, naznačen time što je 5-[(4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil]-2-{(1R)-1-[trans-4-(3-metoksiazetidin-1-il)cikloheksil]etil}-3-metil-5,6,7,8-tetrahidro-4H-tieno[3,2-c]azepin-4-on, ili njegova farmaceutski prihvatljiva sol.
11. Farmaceutski pripravak, naznačen time što sadrži spoj, ili njegovu sol, u skladu s bilo kojim od patentnih zahtjeva 1-10, kao i jednu ili više farmaceutski prihvatljivih pomoćnih tvari, nosača ili razrjeđivača.
12. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time što je namijenjen upotrebi u terapiji.
13. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time što je namijenjen upotrebi u liječenju raka.
14. Spoj, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što se rak bira iz skupine koju čine limfomi, rabdoidni tumori, tumori kojima nedostaje ili im je defektna jedna ili više komponenata kompleksa SWI/SNF, kompleksa MLL, te imaju konstitutivno aktivan PI3K put, sarkomi, multipli mijelom, melanom, gastrointestinalni rak, kolorektalni rak, rak pluća, rak bubrega, rak dojke, rak jajnika, te rak prostate.
15. Spoj, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 14, naznačen time što je rak difuzni limfom velikih B-stanica ili folikularni limfom.
16. Spoj, ili njegova sol, namijenjen upotrebi u skladu s bilo patentnim zahtjevom 14 ili 15, naznačen time što je rak difuzni limfom velikih B-stanica.
17. Spoj, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 14, naznačen time što je rak a rabdoidni tumor kojem nedostaje SNF5.
18. Spoj, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 14, naznačen time što je rak rak želuca.
19. Spoj, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 14, naznačen time što je rak rak jajnika.
20. Spoj, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 14, naznačen time što je rak multipli mijelom.
21. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time što je namijenjen upotrebi u istodobnoj, odvojenoj ili uzastopnoj kombinaciji s karboplatinom i paklitakselom u liječenju raka jajnika.
22. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time što je namijenjen upotrebi u istodobnoj, odvojenoj ili uzastopnoj kombinaciji s oksaliplatinom i paklitakselom u liječenju raka želuca.
23. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time što je namijenjen upotrebi u istodobnoj, odvojenoj ili uzastopnoj kombinaciji s gemcitabinom i cisplatin u liječenju raka pluća.
24. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time što je namijenjen upotrebi u istodobnoj, odvojenoj ili uzastopnoj kombinaciji s irinotekanom i oksaliplatinom u liječenju kolorektalnog raka.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382433 | 2015-08-27 | ||
| EP15382615 | 2015-12-11 | ||
| PCT/US2016/047989 WO2017035060A1 (en) | 2015-08-27 | 2016-08-22 | Inhibitors of ezh2 |
| EP16757513.3A EP3341379B1 (en) | 2015-08-27 | 2016-08-22 | Inhibitors of ezh2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192101T1 true HRP20192101T1 (hr) | 2020-02-21 |
Family
ID=56801893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192101TT HRP20192101T1 (hr) | 2015-08-27 | 2019-11-21 | Inhibitori ezh2 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9718838B2 (hr) |
| EP (1) | EP3341379B1 (hr) |
| JP (1) | JP6704040B2 (hr) |
| KR (1) | KR20180030704A (hr) |
| CN (1) | CN107922434B (hr) |
| AU (1) | AU2016313541A1 (hr) |
| BR (1) | BR112018003108A2 (hr) |
| CA (1) | CA2994428A1 (hr) |
| CO (1) | CO2018002033A2 (hr) |
| CR (1) | CR20180104A (hr) |
| CY (1) | CY1122364T1 (hr) |
| DK (1) | DK3341379T3 (hr) |
| DO (1) | DOP2018000058A (hr) |
| EC (1) | ECSP18014798A (hr) |
| ES (1) | ES2756603T3 (hr) |
| HR (1) | HRP20192101T1 (hr) |
| HU (1) | HUE047630T2 (hr) |
| IL (1) | IL257061A (hr) |
| LT (1) | LT3341379T (hr) |
| MD (1) | MD3341379T2 (hr) |
| ME (1) | ME03650B (hr) |
| MX (1) | MX2018002484A (hr) |
| PE (1) | PE20181025A1 (hr) |
| PH (1) | PH12018500423A1 (hr) |
| PL (1) | PL3341379T3 (hr) |
| PT (1) | PT3341379T (hr) |
| RS (1) | RS59615B1 (hr) |
| SI (1) | SI3341379T1 (hr) |
| TN (1) | TN2018000058A1 (hr) |
| TW (1) | TW201718598A (hr) |
| WO (1) | WO2017035060A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287328B6 (sk) * | 1999-04-22 | 2010-07-07 | Biogen Idec Ma Inc. | Použitie kompozície obsahujúcej homológ protilátky, ktorý je antagonistom interakcie medzi integrínom nesúcim podjednotku alfa4 a ligandom pre integrín nesúci podjednotku alfa4 |
| TW201708210A (zh) * | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產（第二）有限公司 | Ｚｅｓｔｅ同源物２增強子之抑制劑 |
| CA3023157A1 (en) * | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| JP2019527037A (ja) * | 2016-06-08 | 2019-09-26 | ジェネンテック， インコーポレイテッド | がんのための診断及び治療方法 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| CN109942556A (zh) * | 2017-12-21 | 2019-06-28 | 上海青煜医药科技有限公司 | 嘧啶酮化合物及其应用 |
| MX2020007974A (es) | 2018-01-31 | 2020-09-07 | Mirati Therapeutics Inc | Inhibidores de complejo represivo polycomb 2 (prc2). |
| US20210188813A1 (en) * | 2018-04-24 | 2021-06-24 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Ezh2 inhibitor and pharmaceutically acceptable salts and polymorphic substances thereof, and application of ezh2 inhibitor |
| CN112399857A (zh) | 2018-07-09 | 2021-02-23 | 盲人庇护基金会 | Prc2亚单位的抑制治疗眼失调 |
| CN111909157B (zh) * | 2019-05-07 | 2023-02-03 | 南京药石科技股份有限公司 | Ezh2抑制剂及其用途 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002034721A1 (en) * | 2000-10-20 | 2002-05-02 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| PT1303261E (pt) * | 2000-07-24 | 2005-06-30 | Sugen Inc | Sistema para administracao de drogas auto-emulsionaveis, para drogas lipofilas extremamente insoluveis em agua |
| IL161036A0 (en) * | 2001-09-24 | 2004-08-31 | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy | |
| US20070015154A1 (en) | 2003-02-14 | 2007-01-18 | Smithkline Beecham Corporation | Differentially expressed nucleic acids that correlate with ksp expression |
| WO2011140324A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indoles |
| JP5889875B2 (ja) | 2010-05-07 | 2016-03-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | アザインダゾール |
| WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| PL2614369T3 (pl) | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US8765792B2 (en) | 2010-12-01 | 2014-07-01 | Glaxosmithkline Llc | Indoles |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| WO2013039988A1 (en) | 2011-09-13 | 2013-03-21 | Glax0Smithkline Llc | Azaindazoles |
| BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| WO2013067302A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| AU2012332297B2 (en) | 2011-11-04 | 2016-01-07 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013075083A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| NZ628762A (en) | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| TR201904660T4 (tr) | 2012-03-12 | 2019-05-21 | Epizyme Inc | İnsan EZH2 inhibitörleri ve bunun kullanım yöntemleri. |
| CN104350311A (zh) | 2012-04-12 | 2015-02-11 | 纳幕尔杜邦公司 | 罐龙头 |
| EP4140487A1 (en) | 2012-04-13 | 2023-03-01 | Epizyme Inc | Combination therapy for treating cancer |
| NZ700761A (en) | 2012-04-13 | 2016-09-30 | Epizyme Inc | Salt form of a human histone methyltransferase ezh2 inhibitor |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| EP2854811A1 (en) * | 2012-05-31 | 2015-04-08 | Amgen Inc. | Use of amg 900 for the treatment of cancer |
| JP6254169B2 (ja) | 2012-09-28 | 2017-12-27 | ファイザー・インク | ベンズアミドおよびヘテロベンズアミド化合物 |
| KR20190105669A (ko) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| US10092572B2 (en) | 2012-10-15 | 2018-10-09 | Epizyme, Inc. | Substituted benzene compounds |
| RU2015127822A (ru) | 2012-12-13 | 2017-01-16 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Ингибиторы энхансера гомолога 2 белка zeste |
| US20150313906A1 (en) | 2012-12-19 | 2015-11-05 | Glaxosmithkline Llc | Combination |
| WO2014100665A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| CA2894216A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| KR102219441B1 (ko) | 2013-02-11 | 2021-02-23 | 콘스텔레이션 파마슈티칼스, 인크. | 메틸 변형 효소 조절제, 이의 조성물 및 용도 |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| NZ630205A (en) | 2013-04-30 | 2017-03-31 | Glaxosmithkline Intellectual Property (No 2) Ltd | Enhancer of zeste homolog 2 inhibitors |
| WO2015004618A1 (en) | 2013-07-10 | 2015-01-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| EP3022184B1 (en) | 2013-07-19 | 2017-09-27 | Epizyme, Inc. | Substituted benzene compounds |
| EP3022195A2 (en) | 2013-07-19 | 2016-05-25 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| US20160228447A1 (en) | 2013-10-18 | 2016-08-11 | Epizyme, Inc. | Method of treating cancer |
| US9738630B2 (en) | 2013-11-19 | 2017-08-22 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| US9822103B2 (en) | 2013-11-22 | 2017-11-21 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| WO2015104677A1 (en) | 2014-01-10 | 2015-07-16 | Piramal Enterprises Limited | Heterocyclic compounds as ezh2 inhibitors |
| KR102302830B1 (ko) | 2014-03-17 | 2021-09-15 | 다이이찌 산쿄 가부시키가이샤 | 1,3-벤조디옥솔 유도체 |
| WO2015193768A1 (en) | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
| HUE062158T2 (hu) | 2014-06-17 | 2023-10-28 | Epizyme Inc | EZH2 inhibitorok a limfóma kezelésére |
| EA031892B1 (ru) | 2014-06-17 | 2019-03-29 | Пфайзер Инк. | Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2 |
| AU2015276899B2 (en) | 2014-06-19 | 2021-08-12 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to EZH2 inhibitors |
| US20170217941A1 (en) | 2014-06-25 | 2017-08-03 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| AU2015340614B2 (en) | 2014-10-28 | 2018-07-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| WO2016102493A1 (en) | 2014-12-22 | 2016-06-30 | Bayer Pharma Aktiengesellschaft | Imidazopyridine ezh2 inhibitors |
| US20180037568A1 (en) | 2015-02-13 | 2018-02-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2016140501A1 (en) | 2015-03-04 | 2016-09-09 | Kainos Medicine, Inc. | Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors |
| TW201708210A (zh) | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產（第二）有限公司 | Ｚｅｓｔｅ同源物２增強子之抑制劑 |
-
2016
- 2016-08-11 TW TW105125679A patent/TW201718598A/zh unknown
- 2016-08-22 KR KR1020187005603A patent/KR20180030704A/ko not_active Application Discontinuation
- 2016-08-22 HU HUE16757513A patent/HUE047630T2/hu unknown
- 2016-08-22 PT PT167575133T patent/PT3341379T/pt unknown
- 2016-08-22 CN CN201680049957.2A patent/CN107922434B/zh active Active
- 2016-08-22 PE PE2018000313A patent/PE20181025A1/es not_active Application Discontinuation
- 2016-08-22 MD MDE20180644T patent/MD3341379T2/ro unknown
- 2016-08-22 PL PL16757513T patent/PL3341379T3/pl unknown
- 2016-08-22 MX MX2018002484A patent/MX2018002484A/es unknown
- 2016-08-22 RS RS20191526A patent/RS59615B1/sr unknown
- 2016-08-22 JP JP2018510778A patent/JP6704040B2/ja active Active
- 2016-08-22 DK DK16757513T patent/DK3341379T3/da active
- 2016-08-22 WO PCT/US2016/047989 patent/WO2017035060A1/en active Application Filing
- 2016-08-22 LT LT16757513T patent/LT3341379T/lt unknown
- 2016-08-22 CR CR20180104A patent/CR20180104A/es unknown
- 2016-08-22 ES ES16757513T patent/ES2756603T3/es active Active
- 2016-08-22 US US15/242,638 patent/US9718838B2/en active Active
- 2016-08-22 AU AU2016313541A patent/AU2016313541A1/en not_active Abandoned
- 2016-08-22 CA CA2994428A patent/CA2994428A1/en not_active Abandoned
- 2016-08-22 TN TNP/2018/000058A patent/TN2018000058A1/en unknown
- 2016-08-22 BR BR112018003108-9A patent/BR112018003108A2/pt not_active Application Discontinuation
- 2016-08-22 ME MEP-2019-322A patent/ME03650B/me unknown
- 2016-08-22 SI SI201630453T patent/SI3341379T1/sl unknown
- 2016-08-22 EP EP16757513.3A patent/EP3341379B1/en active Active
-
2018
- 2018-01-21 IL IL257061A patent/IL257061A/en unknown
- 2018-02-22 DO DO2018000058A patent/DOP2018000058A/es unknown
- 2018-02-23 CO CONC2018/0002033A patent/CO2018002033A2/es unknown
- 2018-02-26 PH PH12018500423A patent/PH12018500423A1/en unknown
- 2018-02-26 EC ECIEPI201814798A patent/ECSP18014798A/es unknown
-
2019
- 2019-11-21 HR HRP20192101TT patent/HRP20192101T1/hr unknown
- 2019-12-04 CY CY20191101284T patent/CY1122364T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192101T1 (hr) | Inhibitori ezh2 | |
| RU2016130986A (ru) | Ингибитор киназы и его применение | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| HRP20171758T1 (hr) | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene | |
| HRP20171788T1 (hr) | Kombinacija anti-kir antitijela i anti-pd-1 antitijela u liječenju raka | |
| JP2017510661A5 (hr) | ||
| RU2013131004A (ru) | Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek | |
| TN2017000511A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. | |
| JP2016522266A5 (hr) | ||
| JP2017525730A5 (hr) | ||
| HRP20161498T1 (hr) | Inhibitori kinaza i njihova upotreba u liječenju raka | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2015536964A5 (hr) | ||
| MD3313850T2 (ro) | Noi derivaţi de aminoacizi, procedeu pentru prepararea acestora şi compoziţii farmaceutice care îi conţin | |
| CN103327977B (zh) | 恶液质的治疗或预防剂 | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| JP2014518544A5 (hr) | ||
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| JP2015532292A5 (hr) | ||
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| SI2793884T1 (en) | Notch signaling pathway inhibitors and their use in the treatment of various cancers | |
| MX2013003036A (es) | Derivados de pirazina como bloqueadores de enac. |